Brought to you by 
Blueprint signs on its first Big Pharma partner Roche in immuno-oncology deal; terms amended
27 Oct 2021
Executive Summary
Roche received options to license exclusive worldwide discovery, development, and commercialization rights to up to five of Blueprint Medicines Corp.'s small-molecule immunokinase inhibitors in immuno-oncology. The companies may create monotherapies or combinations with Roche's existing drugs or immunotherapies from other companies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Drug Discovery Tools
- Bioinformatics
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Blueprint signs on its first Big Pharma partner Roche in immuno-oncology deal; terms amended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice